Germana Tognon
YOU?
Author Swipe
View article: Supplementary Table S4 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Supplementary Table S4 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer Open
Panel of gene used for the GIScar calculation (n =127)
View article: Clinical Significance of Soluble L1CAM Serum Levels in Patients with High-Risk Endometrial Cancer
Clinical Significance of Soluble L1CAM Serum Levels in Patients with High-Risk Endometrial Cancer Open
Background/Objectives: Despite advances in targeted therapies, a substantial proportion of high-risk endometrial carcinomas (EC) do not respond to treatment and have a poor prognosis. The identification of prognostic and predictive biomark…
View article: Geneva Homologous Recombination Deficiency Test Is Predictive of Survival Benefit From Olaparib and Bevacizumab Maintenance in Ovarian Cancer
Geneva Homologous Recombination Deficiency Test Is Predictive of Survival Benefit From Olaparib and Bevacizumab Maintenance in Ovarian Cancer Open
PURPOSE The ability of the Geneva homologous recombination deficiency (HRD) test to predict progression-free survival (PFS) in patients with high-grade ovarian cancer treated with poly (ADP-ribose) polymerase inhibitors has been demonstrat…
View article: 85P Niraparib customized dosing regimen (RADAR) to manage thrombocytopenia events in platinum-sensitive recurrent ovarian cancer patients: The NEWTON trial
85P Niraparib customized dosing regimen (RADAR) to manage thrombocytopenia events in platinum-sensitive recurrent ovarian cancer patients: The NEWTON trial Open
View article: Unraveling the complexity of HRD assessment in ovarian cancer by combining genomic and functional approaches: translational analyses of MITO16-MaNGO-OV-2 trial
Unraveling the complexity of HRD assessment in ovarian cancer by combining genomic and functional approaches: translational analyses of MITO16-MaNGO-OV-2 trial Open
The study underscores the complexities of HRD assessment and advocates for a combined genomic and functional approach to enhance predictive accuracy in OvC treatment responses.
View article: Impact of metabolism-related markers on outcomes in ovarian cancer patients: Findings of the MITO16A/MaNGO-OV2 trial
Impact of metabolism-related markers on outcomes in ovarian cancer patients: Findings of the MITO16A/MaNGO-OV2 trial Open
Introduction In ovarian cancer, expression of metabolism-related markers has been investigated in several studies focusing on individual markers; however, a parallel quantitative evaluation of markers mapping to distinct metabolic processe…
View article: <scp>TP53</scp> mutations and survival in ovarian carcinoma patients receiving first‐line chemotherapy plus bevacizumab: Results of the <scp>MITO16A</scp>/<scp>MaNGO OV</scp>‐2 study
<span>TP53</span> mutations and survival in ovarian carcinoma patients receiving first‐line chemotherapy plus bevacizumab: Results of the <span>MITO16A</span>/<span>MaNGO OV</span>‐2 study Open
To date, there are no biomarkers that define a patient subpopulation responsive to bevacizumab (BEV), an effective treatment option for advanced ovarian carcinoma (OC). In the context of the MITO16A/MaNGO OV‐2 trial, a Phase IV study of ch…
View article: Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial
Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial Open
PURPOSE To evaluate atezolizumab combined with platinum-based chemotherapy (CT) followed by maintenance niraparib for late-relapsing recurrent ovarian cancer. METHODS The multicenter placebo-controlled double-blind randomized phase III ENG…
View article: 37P Estrogen-mimetic effects of mitotane in patients with adrenocortical carcinoma: Focus on this neglected toxicity
37P Estrogen-mimetic effects of mitotane in patients with adrenocortical carcinoma: Focus on this neglected toxicity Open
Mitotane is the cornerstone of both adjuvant and metastatic treatment of adrenocortical carcinoma (ACC). The side effects of this drug include those related to its estrogenic mimetic action, which has not been well studied. We conducted a …
View article: TP53 mutations are associated with improved survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: results from the MITO16A/MaNGO OV-2 study
TP53 mutations are associated with improved survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: results from the MITO16A/MaNGO OV-2 study Open
PURPOSE Bevacizumab (BEV) is considered an effective treatment option for advanced ovarian carcinoma. However, to date, there are no biomarkers that define a BEV-responsive patient subpopulation. METHODS I…
View article: TP53 mutations are associated with improved survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: results from the MITO16A/MaNGO OV-2 study
TP53 mutations are associated with improved survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: results from the MITO16A/MaNGO OV-2 study Open
PURPOSE Bevacizumab (BEV) is considered an effective treatment option for advanced ovarian carcinoma. However, to date, there are no biomarkers that define a BEV-responsive patient subpopulation. METHODS I…
View article: Normalized LST Is an Efficient Biomarker for Homologous Recombination Deficiency and Olaparib Response in Ovarian Carcinoma
Normalized LST Is an Efficient Biomarker for Homologous Recombination Deficiency and Olaparib Response in Ovarian Carcinoma Open
PURPOSE The efficiency of the Myriad Homologous Recombination Deficiency (HRD) test to guide the use of poly (ADP-ribose) polymerase (PARP) inhibitors has been demonstrated in several phase III trials. However, a need exists for alternativ…
View article: Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trial
Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trial Open
View article: Supplemental Material Section S2 from miRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities
Supplemental Material Section S2 from miRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities Open
PDF file - 126K, Survival analysis methodology and results for each histotype.
View article: Supplemental Material Section S8 from miRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities
Supplemental Material Section S8 from miRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities Open
PDF file - 127K, miR-192 and miR-194 expression values stratified according to tumor grade and survival analysis (OS and PFS). Data shown refers to the entire cohort of 67 stage I mucinous EOC patients.
View article: Supplemental Material Section S6 from miRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities
Supplemental Material Section S6 from miRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities Open
PDF file - 217K, The clinical stratification of the 76 selected patients used for the integrative analysis and the MAGIA2 complete results.
View article: Data from miRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities
Data from miRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities Open
Purpose: Epithelial ovarian cancer (EOC) is one of the most lethal gynecologic diseases, with survival rate virtually unchanged for the past 30 years. EOC comprises different histotypes with molecular and clinical heterogeneity, but…
View article: Supplemental Material Section S8 from miRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities
Supplemental Material Section S8 from miRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities Open
PDF file - 127K, miR-192 and miR-194 expression values stratified according to tumor grade and survival analysis (OS and PFS). Data shown refers to the entire cohort of 67 stage I mucinous EOC patients.
View article: Supplemental Material Section S3 from miRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities
Supplemental Material Section S3 from miRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities Open
PDF file - 162K, Human Ovarian Surface Epithelium (HOSE) experiments and analyses.
View article: Supplemental Material Section S7 from miRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities
Supplemental Material Section S7 from miRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities Open
PDF file - 330K, The clinical stratification of the 76 selected patients used for the integrative analysis and the MAGIA2 complete results.
View article: Supplemental Material Section S5 from miRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities
Supplemental Material Section S5 from miRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities Open
PDF file - 144K, Resampling strategy to identify miRNA markers.
View article: Supplemental Material Section S5 from miRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities
Supplemental Material Section S5 from miRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities Open
PDF file - 144K, Resampling strategy to identify miRNA markers.
View article: Supplemental Material Section S3 from miRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities
Supplemental Material Section S3 from miRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities Open
PDF file - 162K, Human Ovarian Surface Epithelium (HOSE) experiments and analyses.
View article: Data from miRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities
Data from miRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities Open
Purpose: Epithelial ovarian cancer (EOC) is one of the most lethal gynecologic diseases, with survival rate virtually unchanged for the past 30 years. EOC comprises different histotypes with molecular and clinical heterogeneity, but…
View article: Supplemental Material Section S1 from miRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities
Supplemental Material Section S1 from miRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities Open
PDF file - 78K, Tissue sample collection.
View article: Supplemental Material Section S4 from miRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities
Supplemental Material Section S4 from miRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities Open
PDF file - 176K, miRNA expression analysis methodology, the complete lists of differentially expressed genes for each subtype comparison and the relative resampling score.
View article: Supplemental Material Section S7 from miRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities
Supplemental Material Section S7 from miRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities Open
PDF file - 330K, The clinical stratification of the 76 selected patients used for the integrative analysis and the MAGIA2 complete results.
View article: Supplemental Material Section S4 from miRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities
Supplemental Material Section S4 from miRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities Open
PDF file - 176K, miRNA expression analysis methodology, the complete lists of differentially expressed genes for each subtype comparison and the relative resampling score.
View article: Supplemental Material Section S6 from miRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities
Supplemental Material Section S6 from miRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities Open
PDF file - 217K, The clinical stratification of the 76 selected patients used for the integrative analysis and the MAGIA2 complete results.
View article: Supplemental Material Section S1 from miRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities
Supplemental Material Section S1 from miRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities Open
PDF file - 78K, Tissue sample collection.